In the July 10, 2018, issue of The ASCO Post, the article “KEYNOTE-407: Pembrolizumab Plus Chemotherapy Benefits Response, Survival in Squamous NSCLC” contained an error in the regimen for pembrolizumab (Keytruda). The study regimen, which has been corrected in the online version on ASCOPost.com, should have been described as follows:
Patients were randomized 1:1 to receive pembrolizumab at 200 mg every 3 weeks plus carboplatin AUC 6 every 3 weeks and paclitaxel at 200 mg/m2 every 3 weeks or nanoparticle albumin-bound (nab)-paclitaxel at 100 mg/m2 every week for 4 cycles vs the same chemotherapy plus placebo. The experimental arm received further pembrolizumab for up to 31 cycles, whereas the control arm received placebo.
We regret the error and apologize for any confusion. ■
